# Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

> **NCT01491672** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT01491672
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491672, "Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01491672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*